SOURCE: AmStem Corporation (Stem Cell Therapy International, Inc.)

 AmStem Corporation (Stem Cell Therapy International, Inc.)

February 23, 2010 13:00 ET

AmStem Corporation Announces Ticker Symbol Change to AMST Effective Today

TAMPA, FL--(Marketwire - February 23, 2010) - AmStem Corporation (OTCBB: AMST) announces that it has received approval from the Financial Industry Regulatory Authority (FINRA) for the Company's name change to AmStem Corporation from Stem Cell Therapy International and for its ticker symbol change to AMST from SCII as quoted on the Over the Counter Bulletin Board effective today, February 23, 2010. The name and ticker change reflect the Company's new operational structure following its recent merger with Histostem Ltd. of South Korea. This merger has created one of the first fully merged Pacific Rim stem cell companies and cord blood repositories within a U.S. entity.

About AmStem Corporation

AmStem Corporation (OTCBB: SCII) is in the field of regenerative medicine. The Company is devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products.

About AmStem International Inc.

Amstem International Inc. ("AmStem") is a new biotechnology company based in Northern California in the watershed of stem cell innovation fueled by President Obama's recent announcement to lift Federal funding limitations for stem cell research. AmStem provides biotherapeutic and cosmetic stem cell products, stem cell collection and storage know-how, and access to nanotechnology vital to cutting edge stem cell research. Its web site is under construction at

About Histostem Co. Ltd.

Histostem was founded in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has approximately 50 full-time employees and several part-time employees. Histostem's intellectual property portfolio consists of 6 patents that have been granted and 5 patents pending. To its knowledge, Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology. A comprehensive list of Histostem's achievements can be found at the company's website, (click on English version when entering the site).

Forward-Looking Statements

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for AmStem Corporation, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, successfully complete clinical trials, our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Contact Information